Streptozotocin Manufacturing Plant Project Report 2026: Cost Analysis, ROI, and Feasibility Insights

Streptozotocin is produced through submerged aerobic fermentation using Streptomyces achromogenes. The fermentation uses a nutrient medium containing carbon and nitrogen sources and minerals, followed by recovery, purification, concentration, and drying to obtain the final product. Streptozotocin is a naturally occurring compound produced by Streptomyces achromogenes.

The key biological input is the Streptomyces achromogenes culture, while glucose or other carbon sources, nitrogen sources, minerals, and process aids form the main fermentation inputs. Fermentation media and biological inputs can represent approximately 35% to 50% of total raw material costs, while the remaining cost is associated with downstream recovery, purification, solvents, and processing materials.

Key cost drivers include the quality and availability of the Streptomyces achromogenes culture, fermentation medium costs, fermentation yield, downstream recovery and purification efficiency, energy, labor, controlled storage, quality testing, and GMP compliance. Fermentation yield and downstream recovery are particularly important because losses at these stages can increase the cost per unit of finished product.

Manufacturing for pharmaceutical use requires compliance with applicable GMP requirements, validated manufacturing and quality-control processes, appropriate impurity and potency testing, controlled storage and handling, and complete batch documentation. For the US market, FDA requirements apply to approved pharmaceutical products and applicable manufacturing facilities, while EMA and national requirements apply in European markets. A DMF or equivalent regulatory dossier may be required when the substance is supplied as an API or manufacturing component, depending on the product and regulatory pathway.